Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) rose 24.1% on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. Approximately 892,106 shares changed hands during trading, an increase of 556% from the average daily volume of 135,968 shares. The stock had previously closed at C$1.37.
Wall Street Analyst Weigh In
Separately, Jones Trading downgraded Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Report on ONC
Oncolytics Biotech Trading Up 6.0%
The stock has a market capitalization of C$123.32 million, a PE ratio of -4.46 and a beta of 1.35. The firm has a 50 day moving average price of C$0.81 and a 200 day moving average price of C$0.94. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
